Bank of America
CLDX icon

Bank of America’s Celldex Therapeutics CLDX Stock Holding History

Bank of America’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.5M Buy
708,647
+293,759
+71% +$8.01M ﹤0.01% 2285
2025
Q4 		$11.3M Buy
414,888
+76,077
+22% +$2M ﹤0.01% 2760
2025
Q3 		$8.77M Buy
338,811
+62,627
+23% +$1.45M ﹤0.01% 3432
2025
Q2 		$5.62M Buy
276,184
+31,248
+13% +$608K ﹤0.01% 3778
2025
Q1 		$4.45M Buy
244,936
+202,088
+472% +$4.52M ﹤0.01% 3931
2024
Q4 		$1.08M Sell
42,848
-175,590
-80% -$4.77M ﹤0.01% 4967
2024
Q3 		$7.42M Sell
218,438
-28,673
-12% -$1.09M ﹤0.01% 3367
2024
Q2 		$9.15M Sell
247,111
-24,500
-9% -$924K ﹤0.01% 3029
2024
Q1 		$11.4M Buy
271,611
+53,797
+25% +$2.21M ﹤0.01% 2874
2023
Q4 		$8.64M Buy
217,814
+5,557
+3% +$163K ﹤0.01% 3038
2023
Q3 		$5.84M Sell
212,257
-142,664
-40% -$4.47M ﹤0.01% 3263
2023
Q2 		$12M Sell
354,921
-6,596
-2% -$222K ﹤0.01% 2529
2023
Q1 		$13M Buy
361,517
+208,217
+136% +$8.98M ﹤0.01% 2553
2022
Q4 		$6.83M Buy
153,300
+22,310
+17% +$796K ﹤0.01% 3084
2022
Q3 		$3.68M Buy
130,990
+49,268
+60% +$1.51M ﹤0.01% 3662
2022
Q2 		$2.2M Sell
81,722
-99,172
-55% -$2.88M ﹤0.01% 4223
2022
Q1 		$6.16M Buy
180,894
+86,457
+92% +$2.76M ﹤0.01% 3396
2021
Q4 		$3.65M Buy
94,437
+68,077
+258% +$2.97M ﹤0.01% 3972
2021
Q3 		$1.42M Buy
26,360
+13,668
+108% +$641K ﹤0.01% 4756
2021
Q2 		$425K Sell
12,692
-3,441
-21% -$94.5K ﹤0.01% 5553
2021
Q1 		$333K Buy
16,133
+4,301
+36% +$98.8K ﹤0.01% 5679
2020
Q4 		$207K Sell
11,832
-3,052
-21% -$54.9K ﹤0.01% 5581
2020
Q3 		$221K Buy
14,884
+14,831
+27,983% +$174K ﹤0.01% 5237
2020
Q2 		$1K Sell
53
-45
-46% -$199 ﹤0.01% 6720
2020
Q1 		$0 Sell
98
-117
-54% -$264 ﹤0.01% 6879
2019
Q4 		$0 Sell
215
-43
-17% -$100 ﹤0.01% 7108
2019
Q3 		$0 Buy
258
+43
+20% +$100 ﹤0.01% 7272
2019
Q2 		$1K Buy
215
+139
+183% +$472 ﹤0.01% 7014
2019
Q1 		$0 Sell
76
-20
-21% -$105 ﹤0.01% 7133
2018
Q4 		$0 Sell
96
-2,139
-96% -$10.5K ﹤0.01% 7133
2018
Q3 		$15K Sell
2,235
-5,746
-72% -$40.2K ﹤0.01% 6567
2018
Q2 		$60K Sell
7,981
-2,293
-22% -$30.7K ﹤0.01% 6041
2018
Q1 		$359K Buy
10,274
+3,019
+42% +$117K ﹤0.01% 5039
2017
Q4 		$308K Sell
7,255
-1,545
-18% -$66.2K ﹤0.01% 5207
2017
Q3 		$378K Buy
8,800
+1,878
+27% +$70.4K ﹤0.01% 5107
2017
Q2 		$256K Sell
6,922
-2,020
-23% -$89.3K ﹤0.01% 5205
2017
Q1 		$484K Buy
8,942
+657
+8% +$34.2K ﹤0.01% 4905
2016
Q4 		$440K Buy
8,285
+2,246
+37% +$128K ﹤0.01% 4883
2016
Q3 		$365K Sell
6,039
-2,130
-26% -$133K ﹤0.01% 4824
2016
Q2 		$538K Sell
8,169
-4,951
-38% -$314K ﹤0.01% 4610
2016
Q1 		$744K Buy
13,120
+4,747
+57% +$534K ﹤0.01% 4317
2015
Q4 		$1.97M Sell
8,373
-2,514
-23% -$548K ﹤0.01% 3809
2015
Q3 		$1.72M Buy
10,887
+2,031
+23% +$575K ﹤0.01% 3900
2015
Q2 		$3.35M Buy
8,856
+2,198
+33% +$873K ﹤0.01% 2970
2015
Q1 		$2.78M Sell
6,658
-479
-7% -$171K ﹤0.01% 2936
2014
Q4 		$1.95M Buy
7,137
+192
+3% +$47.7K ﹤0.01% 3402
2014
Q3 		$1.35M Buy
6,945
+2,052
+42% +$447K ﹤0.01% 3741
2014
Q2 		$1.2M Sell
4,893
-181
-4% -$40.9K ﹤0.01% 3839
2014
Q1 		$1.34M Buy
5,074
+553
+12% +$212K ﹤0.01% 3599
2013
Q4 		$1.64M Buy
4,521
+4,067
+896% +$1.57M ﹤0.01% 3520
2013
Q3 		$241K Sell
454
-427
-48% -$146K ﹤0.01% 5290
2013
Q2 		$206K Buy
+881
New +$173K ﹤0.01% 5588

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America's CLDX Position: Q1 2026 in Review

Bank of America increased its Celldex Therapeutics (CLDX) stake by 71% in Q1 2026, buying an estimated $8.01M and bringing the position to 708,647 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Bank of America first reported a position in CLDX in Q2 2013 and has held it in 52 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Bank of America held 708,647 shares of Celldex Therapeutics worth $22.5M as of Q1 2026.
  • Bank of America bought 293,759 Celldex Therapeutics shares in Q1 2026, an estimated $8.01M.
  • Celldex Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2285 holding.
  • Bank of America first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.